抑郁症治疗靶标及其药物研发进展  

Progress of development and research on targets and drugs for major depressive disorder

作　　者：冯殿伟[1] 

机构地区：[1]天津市精神卫生中心,天津300222

出　　处：《中国医院药学杂志》2018年第4期443-449,共7页Chinese Journal of Hospital Pharmacy

摘　　要：抑郁症的发病机制至今仍未完全阐明。传统的抗抑郁药是基于单胺递质假说而开发的。近年来,除了单胺类外,谷氨酸系统、HPA轴等一些新的抑郁症治疗靶标逐渐成为研究热点,基于这些靶标研发的新型抗抑郁药已取得重大进展,本文就抑郁症的治疗靶标和新药研发情况作一综述,为临床治疗和开发新药提供参考。The pathogenesis of major depressive disorder has not been fully elucidated.Conventional antidepressants were developed based on the monoamine transmitter hypothesis.In recent years,in addition to monoamine,some new targets such as glutamate system,HPA axis,etc.in the treatment of major depressive disorders have become hot research topics.The new antidepressants based on these targets have made significant progresses.In this paper,progresses of development and research on targets and new drugs for major depressive disorder have been reviewed to provide references for clinical treatment and new drugs development.

关 键 词：抑郁症 靶标 抗抑郁药 进展 

分 类 号：R969.3[医药卫生—药理学]